[ADHD] Alcobra Ltd.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 113.55 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.35 Change: 0.05 (2.17%)
Ext. hours: Change: 0 (0%)

chart ADHD

Refresh chart

Description: Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of proprietary drug candidates. It offers most advanced product (MDX) for the treatment of attention deficit hyperactivity disorder (ADHD) and other cognitive dysfunctions, including Fragile X. The company has initiated a Phase III clinical trial in the United States for the use of MDX to treat ADHD in adults. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding27.56 M EPS-0.89 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-1.26
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities8.41 M Cash From Operating Activities-28.33 M Gross Profit
Net Profit-6.8 M Operating Profit-6.83 M Total Assets22.32 M Total Current Assets22.13 M
Total Current Liabilities2.38 M Total Debt Total Liabilities2.38 M Total Revenue
Technical Data
High 52 week10.22 Low 52 week0.94 Last close10.22 Last change0%
RSI96.67 Average true range0.94 Beta2.04 Volume115.85 K
Simple moving average 20 days338.82% Simple moving average 50 days535.18% Simple moving average 200 days712.37%
Performance Data
Performance Week635.25% Performance Month576.82% Performance Quart922% Performance Half766.1%
Performance Year370.97% Performance Year-to-date386.67% Volatility daily41.65% Volatility weekly93.14%
Volatility monthly190.87% Volatility yearly661.2% Relative Volume385.84% Average Volume1.11 M
New High New Low

News

2017-11-16 07:00:00 | Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market

2017-11-09 07:17:34 | Alcobra reports 3Q loss

2017-11-09 07:00:00 | Alcobra Announces Third Quarter 2017 Financial Results and Provides Corporate Update

2017-11-02 08:01:27 | Arcturus Therapeutics to Host Key Opinion Leader Call on Advances in Delivery of Nucleic Acid Medicines on Tuesday, November 7

2017-10-31 08:00:00 | Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics

2017-10-26 08:00:00 | Arcturus Therapeutics Announces Presentations at Conferences in November

2017-10-20 08:10:00 | Today's Research Reports on Stocks to Watch: Alcobra and Imprimis Pharmaceuticals

2017-10-19 12:04:11 | Alcobra Ltd ADHD Stock Fires Up To The Roof; Here’s Why

2017-10-19 07:00:00 | Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines

2017-10-06 08:00:00 | Arcturus Therapeutics, Inc. to Present at the Chardan Gene Therapy Conference

2017-10-05 20:25:25 | Should You Be Concerned About Alcobra Ltd’s ADHD Risks?

2017-09-27 18:19:56 | Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge

2017-08-11 23:09:03 | Alcobra reports 2Q loss

2017-08-11 08:00:00 | Alcobra Announces Second Quarter 2017 Financial Results and Provides Corporate Update

2017-07-21 08:30:12 | BioLine Rx BLRX Catches Eye: Stock Adds 5.2% in Session

2017-07-20 10:46:02 | New Strong Buy Stocks for July 20th

2017-06-26 08:15:00 | Featured Company News - Gilead's Vosevi Receives Positive Opinion from European CHMP; Set to Deliver Advanced Treatment for All HCV Genotypes

2017-06-23 07:00:00 | Alcobra Updates on its Review of Strategic Alternatives

2017-06-21 04:32:49 | Shire wins U.S. approval for long-acting ADHD drug

2017-06-20 19:19:38 | Shire's long-acting ADHD drug wins U.S. approval

2017-06-12 08:36:48 | Alcobra Announces Cooperation Agreement with Brosh Group and Board Additions

2017-05-31 00:01:01 | Swiss biotech NLS Pharma's ADHD drug succeeds in mid-stage study

2017-05-30 08:31:07 | Alcobra reports 1Q loss

2017-05-30 08:00:00 | Alcobra Announces First Quarter 2017 Financial Results and Provides Corporate Update

2017-05-16 15:34:40 | Chuck Royce Continues to Buy These 10 Stocks

2017-05-15 08:00:00 | Alcobra Announces Leadership Update

2017-05-05 12:43:24 | Alcobra Provides Update on Cancellation of Extraordinary Meeting Called by Brosh Group

2017-04-24 06:00:00 | Alcobra Mails Proxy Materials for Extraordinary General Meeting of Shareholders

2017-04-12 09:05:00 | Exodus Capital is Summoning an Extraordinary General Meeting

2017-04-07 07:30:00 | Tenax Therapeutics and Alcobra Find Rough Waters Ahead

2017-04-05 08:00:00 | Alcobra Provides Update on Request for Extraordinary General Meeting

2017-03-28 10:21:00 | SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Alcobra Ltd.

2017-03-16 12:35:00 | Brosh Capital Delivers Extraordinary General Meeting Request To Alcobra And Issues Letter To Chairman

2017-03-15 11:53:00 | IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alcobra, Ltd., and Encourages Investors with Losses to Contact the Firm

2017-03-09 11:31:00 | IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alcobra, Ltd., and Encourages Investors with Losses to Contact the Firm

2017-03-07 08:00:00 | Alcobra Ltd. to Participate in Upcoming Healthcare Conferences

2017-03-03 10:20:00 | INVESTOR ALERT: Lundin Law PC Announces an Investigation of Alcobra, Ltd. and Encourages Investors with Losses to Contact the Firm

2017-03-01 09:00:00 | INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Alcobra, Ltd. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

2017-03-01 08:00:00 | Alcobra to Host Investor Forum and Webcast on March 28 in New York City

2017-02-24 20:04:00 | IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alcobra, Ltd., and Encourages Investors with Losses to Contact the Firm

2017-02-24 18:00:00 | IMPORTANT ALCOBRA LTD. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the Southern District of New York on behalf of purchasers of Alcobra Ltd.

2017-02-24 11:04:00 | SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Alcobra, Ltd. and Encourages Investors with Losses to Contact the Firm

2017-02-24 10:30:00 | Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Alcobra Ltd. Investors and Encourages Investors to Contact the Firm

2017-02-23 16:51:00 | The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Alcobra Ltd. Investors and Encourages Investors to Contact the Firm

2017-02-23 11:02:00 | INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Alcobra, Ltd. and Encourages Investors with Losses to Contact the Firm

2017-02-17 17:11:00 | Lifshitz & Miller LLP Files Class Action Lawsuit against Alcobra, Ltd.

2017-02-17 08:15:00 | Blog Coverage Ardelyx Reports Positive Data for the Treatment for Hyperphosphatemia in Patients with End-Stage Renal disease

2017-02-15 12:06:20 | Edited Transcript of ADHD earnings conference call or presentation 15-Feb-17 1:30pm GMT

2017-02-15 07:26:27 | Alcobra reports 4Q loss

2017-02-15 07:07:01 | Q4 2016 Alcobra Ltd Earnings Release - 08:30 am ET